companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories














  • Genentech: TNKase® (tenecteplase) - Information for Patients
    Tenecteplase is an enzyme that, when present in blood in pharmacologic concentrations, remains active under in vitro conditions This can lead to degradation of fibrinogen in blood samples removed for analysis
  • Acute Ischemic Stroke Treatment | TNKase® (tenecteplase)
    Tenecteplase is an enzyme that, when present in blood in pharmacologic concentrations, remains active under in vitro conditions This can lead to degradation of fibrinogen in blood samples removed for analysis
  • Tenecteplase - Wikipedia
    Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese hamster ovary cells) [1]
  • Tenecteplase Uses, Side Effects Warnings - Drugs. com
    What is tenecteplase? Tenecteplase is used in adults to treat a stroke caused by a clot (acute ischemic stroke) and to lower the risk of death from a certain type of heart attack Tenecteplase may also be used for purposes not listed in this medication guide
  • Tenecteplase - STROKE MANUAL
    tenecteplase (METALYSE) is a genetically modified form of tissue plasminogen activator (tPA) with increased resistance to PAI, greater fibrin specificity, and a longer half-life (17±7min), allowing for a single bolus administration
  • Tenecteplase (TNK-tPA) • LITFL • CCC
    Tenecteplase is a tissue plasminogen activator used as a thrombolytic medication in: Acute Ischaemic Strokes, Acute Myocardial Infarction, PE
  • Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic . . .
    Current evidence supports the time and cost benefits of tenecteplase, suggesting that it could potentially replace alteplase as the main option for thrombolytic therapy, especially in patients with large vessel occlusion
  • Tenecteplase for Acute Ischemic Stroke Thrombolysis
    The utilization of a newer fibrinolytic agent, tenecteplase, in routine stroke care is increasing because of recent clinical trial findings, streamlined clinical workflows, and cost-effectiveness




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer